News >

Management of Newly Diagnosed mCRC Driven by Molecular Markers

Caroline Seymour
Published: Tuesday, Jun 11, 2019

Wells A. Messersmith, MD

Wells A. Messersmith, MD

The average survival of patients with metastatic colorectal cancer (mCRC) hovers around 3 years, but by understanding where the tumor originated and the increasing array of molecular markers, clinicians have a better chance of optimizing outcomes, explained Wells A. Messersmith, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication